Europe Approved Sutent for Rare Pancreatic Cancer

Print pagePDF pageEmail page

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET).  

The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression. 

The approval was based on a Phase III study which was reported in January.  The study showed that patients with pancreatic NET and treated with Sutent had progression-free survival of 1.4 months, compared with 5.5 months for placebo. 

Please visit healthreason.com for more health related articles.

This entry was posted in Cancer, Pancreatic Cancer and tagged , , , , , . Bookmark the permalink.